Latest:
Dr Bhat on Selecting Between Liso-Cel and Pirtobrutinib in Relapsed/Refractory CLL
Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sylvie Bonvalot, MD, PhD, HDR
Latest:
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Nagla Abdel Karim, MD
Latest:
Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLC
Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.
Christian Marth, MD, PhD
Christian Marth, MD, PhD, is a professor in and head of the Department of Obstetrics and Gynecology at Innsbruck Medical University in Austria.
Latest:
Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: Five-Year and Post-(Neo)Adjuvant Outcomes From KEYNOTE-775 and LEAP-001
Christian Marth, MD, PhD discusses long-term efficacy and safety results from KEYNOTE-775 and LEAP-001. Data include patients with advanced or recurrent endometrial cancer after prior systemic therapy. Follow-up duration was approximately 5 years for KEYNOTE-775 and 4 years for LEAP-001.
B. Douglas Smith, MD
Latest:
Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial
Dr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.
J. Michael Guenther, M.D., Surgical Oncologist, St. Elizabeth Physicians, Edgewood, Kentucky
Latest:
DecisionDx®-Melanoma is designed to identify cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy without experiencing early recurrence
Sponsored content by Castle Biosciences, Inc. Dr. Guenther has not been compensated in connection with this article; Dr. Guenther receives compensation for his participation on the Speaker’s bureau for Castle Biosciences.
Nataliya V. Uboha, MD, PhD
Nataliya Uboha, MD, PhD, a medical oncologist at University of Wisconsin Health, as well as an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health
Latest:
Key Takeaways and Future Questions in Perioperative GC/GEJC
Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.